|Tropical Journal of Pharmaceutical Research|
|Official Journal of Pharmacotherpy Group|
|Home||Pharmacotherapy Group||African Journals Online|
Comparative bioavailability study of a new quinine suppository and oral quinine in healthy volunteers
Chinedum P Babalolaa, AS Adebayob, A Omotosoa, Olubukola Ayindeaa
aDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ibadan, Nigeria
bDrug Research and Development Unit (DRPU), Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
Tropical Journal of Pharmaceutical Research 2004; 3(1): 291-297
Purpose: There is the need for alternative and more convenient route of quinine (QN) administration in complicated and severe malaria. The purpose of this study is to compare the bioavailability (BA) of a new quinine suppository made from theobroma oil to that of an existing tablet formulation in healthy volunteers.
Methods: Six healthy volunteers were administered with 300 mg of QN sulphate as suppository and tablet in a crossover manner. QN concentrations in both plasma and urine at predetermined time points were determined spectrofluorimetrically.
Results: Absorption was slower, more variable and lower with the suppository than with the tablet. The time of maximum concentration (Tmax), maximum concentration (Cmax), area under the curve (AUC) and cumulative urinary excretion (Du¥) for the two formulations were also significantly different, with no changes in elimination half-life (t1/2). The respective Cmax and AUC values were 4 to 5 times higher with the tablet (2.32 ± 0.22 mg/ml, 36.31 ± 10.06 mg.h/ml) than with the suppository (0.52 ± 0.37 mg/ml, 7.69 ± 5.79 mg.h/ml). The Du¥ were 9.17 ± 1.11 mg and 2.56 ± 0.55 mg for the tablet and suppository respectively. The relative BA of the suppository was 21.24 ± 16.00 % (95 % C. I., 8.44 – 34.04%) from plasma levels and 26.14 ± 7.80 % (95 C.I., 19.90 – 32.38 %) from urine excretion.
Conclusion: Absorption of this new QN suppository is poor; therefore it may not be therapeutically expedient to substitute it for the tablet form at the same dose. Improving the suppository formulation or increasing the dose in order to increase its BA may be necessary.
Key words: Quinine, suppository, bioavailability.
To whom correspondence should be addressed: Tel: 0805-522-4989 E-mail: email@example.com
|Copyright @2002-2006. TJPR Faculty of Pharmacy, University of Benin, Benin City, Nigeria|
|Tel: +234 802 3360318 Fax: +234 52 602257 E-mail: firstname.lastname@example.org email@example.com firstname.lastname@example.org|
|Last updated: March 26, 2006|